GGrantIndex
← Leaderboards

Eduard Sanders

University Of Washington

$2,569,663
Attributed
$5,139,325
Total exposure
3
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY201625
$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,139,325 · 3

By mechanism

R01$4,756,325 · 2
R34$383,000 · 1

Top collaborators

Most similar at University Of Washington

Same institution · by research overlap

Others in their field

Top investigators on “Resources

Research focus

ResourcesStandard Of CareCaringPublic HealthUniversitiesAfrica South Of The SaharaAfricanLeadTransmission ProcessInfectionCost EffectiveCost Effectiveness AnalysisParticipantCost EffectivenessClinical TrialsKenyaDiagnosisPoint Of CareCostEfficacy EvaluationProviderHiv InfectionsAdherenceScience

Grant awards (11)

WHO-recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya$646,815
R01 · FY2025 · AI
WHO-recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya$290,440
R01 · FY2025 · AI
WHO-recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya$257,502
R01 · FY2025 · AI
Addressing mental health and HIV medication adherence among high-risk men in a resource-limited setting$111,966
R34 · FY2025 · MH
Addressing mental health and HIV medication adherence among high-risk men in a resource-limited setting$72,503
R34 · FY2025 · MH
WHO-recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya$1,245,739
R01 · FY2024 · AI
Addressing mental health and medication adherence among MSM in South Africa$198,531
R34 · FY2024 · MH
Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmission$561,795
R01 · FY2019 · AI
Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmission$576,362
R01 · FY2018 · AI
Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmission$572,643
R01 · FY2017 · AI
Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmission$605,029
R01 · FY2016 · AI